The laboratory of Atta Behfar, M.D., Ph.D., uses state-of-the-art technologies developed at Mayo Clinic to understand heart disease at its most elemental level. With this understanding, Dr. Behfar and his colleagues are doing cardiovascular regeneration research with the aim of developing novel therapies to prevent and cure chronic heart conditions.
Specifically, the group led by Dr. Behfar focuses on development and use of both stem cells and protein-based therapies to reverse injury caused by lack of blood flow to the heart.
- Development and application of a ready-to-use protein-based technology to protect the heart at the time of infarction
- Application of highly reparative cardiopoietic stem cell technology to a broad range of heart failure conditions
- Phase III clinical testing of cardiopoietic stem cells in patients with end-stage heart failure
- First-in-human, or Phase Ib, testing of cardiopoietic stem cells in the setting of heart surgery:
- Valvular heart disease with low ejection fraction
- Ischemic and nonischemic heart disease requiring left ventricular assist device (LVAD) implantation
- Ischemic heart disease requiring coronary artery bypass graft surgery (CABG)
- Development and validation of a rapid diagnostic panel to identify patients at highest risk of heart failure following a heart attack
- Optimization and preclinical testing of protein delivery to the heart following infarction
Significance to patient care
By 2020, as many as 1 in 5 people in the United States will have heart disease. Cardiovascular regeneration work done at Mayo Clinic offers new hope to patients with chronic heart conditions that can only be palliated by current standards of care — leaving the underlying issue untreated. With a track record of translating regenerative therapies from research into clinical application, Dr. Behfar and his colleagues aim to develop technologies that will repair heart tissue, significantly improving the quality of life in heart disease patients.
As the R. Scott Braswell, Jr., and Mary Lou P. Braswell Deputy Director for Translation and Director of the Van Cleve Cardiac Regenerative Medicine Program in the Mayo Clinic Center for Regenerative Medicine, Dr. Behfar ensures technological and translational readiness and provides oversight of technological platforms, infrastructure and clinical trials to advance new knowledge to clinical applications.
- R. Scott Braswell, Jr., and Mary Lou P. Braswell Deputy Director for Translation, Mayo Clinic Center for Regenerative Medicine, 2018-2021
- Director, Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic, 2014-present
- Recipient, Herman K. Gold Young Investigator Award, American College of Cardiology, 2010
- Foundation Fellow, Clinician Investigator Program, General Mills, 2009-present
- Recipient, Presidential Award, American Society for Clinical Pharmacology and Therapeutics, 2005